薬剤溶出ステント：市場洞察・競合環境・市場予測 (～2030年)

薬剤溶出ステントの市場規模は、2023年の24億米ドルから、予測期間中はCAGR 7.88％で推移し、2030年には37億8,000万米ドルの規模に成長すると予測されています。 薬剤溶出ステントの市場は、心房細動や冠動脈疾患 (CAD) 、末梢動脈疾患 (PAD) を含む心血管疾患の患者数の増加、革新的な製品開発活動、低侵襲技術の採用増加などを主因として大幅な市場成長を遂げており、2024年から2030年までの予測期間中もこれらの要因が市場全体の成長を促進すると予測されています。

薬剤溶出ステント：市場力学

World Heart Report (2023) が提供したデータによると、2021年には、世界で5億人以上が心血管疾患を抱えて生活していると報告されています。さらに、American Heart Association (2023年) が提供した最近のデータによると、2030年までに世界で1,200万人以上が心房細動に罹患すると推定されています。

また、British Heart FoundationのGlobal Heart & Circulatory Diseases Factsheet (2024) によると、世界中で約2億人が冠動脈疾患 (CAD) に罹患しています。

さらに、American Heart Association (2023年) のデータによると、世界平均で約2億人が末梢動脈疾患 (PAD) を抱えて生活しています。また、Global Burden of Disease (2019) によると、2019年の40歳から70歳までのPAD有病者数は世界で5,640万人と推計されています。

このような心血管疾患の患者数の増加は、薬剤溶出ステントの需要を大幅に増加させています。これらの疾患が世界的に広まる中で、ステント留置術のような効果的で低侵襲の治療に対するニーズが高まっています。ステント技術の進歩に加え、心臓や循環器系疾患の負担が増加していることから、ステントはこれらの疾患の治療に不可欠な要素となっており、予防と治療の両方のヘルスケア戦略における役割を高めています。

コーティング別では、ポリマーベースコーティングの部門が2023年に大きな収益シェアを占めると予想されています。これは、薬剤溶出ステントのポリマーベースコーティングのさまざまな特徴と用途によるものです。

薬剤溶出ステントに施されるポリマーベースコーティングは、治療薬の制御放出を促進し、冠動脈の再狭窄防止に非常に効果的です。これらのコーティングは抗増殖薬や抗炎症薬などの薬剤をステント部位で直接、段階的かつ標的的に放出できるように設計されています。これは再狭窄の一般的な原因である平滑筋細胞の増殖や新生内膜過形成を抑制するのに役立ちます。さらに、ポリマーは特定の親水性や疎水性に調整することができ、薬剤の放出速度を調節して治療効果を最適化することができます。

地域別では、北米が薬剤溶出ステント市場で大きな収益シェアを占めると推定されています。これは、CAD、心筋梗塞、およびそれに関連する危険因子の患者数の多さ、製品開発と規制承認の著しい進展、主要企業の存在、確立された高度医療インフラのアベイラビリティなど、いくつかの要因によるものです。

当レポートでは、世界の薬剤溶出ステントの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 薬剤溶出ステント市場レポート：イントロダクション

• 調査範囲
• 市場の分類
• 市場の想定

第2章 薬剤溶出ステント市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 薬剤溶出ステント市場：主要要因分析

• 市場促進要因
  • 慢性疾患の発生率の増加
  • 製品開発活動の活発化
  • 生活習慣病の増加
  • 低侵襲手術への関心
• 市場抑制要因と課題
  • 薬剤溶出ステントに伴うリスクと合併症
  • 厳格な規制承認プロセス
• 市場機会
  • 生体吸収性血管スキャフォールドの開発
  • ステント留置のためのAIとロボットの統合

第6章 薬剤溶出ステント市場：ポーターのファイブフォース分析

第7章 薬剤溶出ステント市場の評価

• タイプ別
  • 冠動脈ステント留置
  • 末梢ステント留置
• スキャフォールド別
  • プラチナクロム
  • コバルトクロム
  • ニチノール
  • その他
• コーティング別
  • ポリマーベースコーティング
  • ポリマーフリーコーティング
• 薬剤タイプ別
  • エベロリムス
  • パクリタキセル
• エンドユーザー別
  • 病院
  • 外来手術センター
  • 専門クリニック
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 薬剤溶出ステント市場：企業・製品プロファイル

• Medtronic
• Abbott
• Boston Scientific Corporation
• B. Braun Melsungen AG
• BIOTRONIK SE & Co. KG
• Cook
• Terumo Corporation
• Lepu Medical Technology Co.,Ltd
• Microport Scientific Corporation
• Balton Sp.z.o.o
• ENDOCOR GmbH
• Eurocor Tech GmbH
• Alvimedica
• Biosensors International Group, Ltd.
• Meril Life Sciences Pvt. Ltd.
• Translumina
• Sino Medical Sciences Technology Inc.
• iVascular S.L.U
• Sahajanand Laser Technology Limited
• Cardionovum GmbH

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Drug-Eluting Stents Market in Global (2021-2030)
• Table 3: Drug-Eluting Stents Market in Global by Type (2021-2030)
• Table 4: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
• Table 5: Drug-Eluting Stents Market in Global by Coating (2021-2030)
• Table 6: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
• Table 7: Drug-Eluting Stents Market in Global by End-User (2021-2030)
• Table 8: Drug-Eluting Stents Market in Global by Geography (2021-2030)
• Table 9: Drug-Eluting Stents Market in North America (2021-2030)
• Table 10: Drug-Eluting Stents Market in the United States (2021-2030)
• Table 11: Drug-Eluting Stents Market in Canada (2021-2030)
• Table 12: Drug-Eluting Stents Market in Mexico (2021-2030)
• Table 13: Drug-Eluting Stents Market in Europe (2021-2030)
• Table 14: Drug-Eluting Stents Market in France (2021-2030)
• Table 15: Drug-Eluting Stents Market in Germany (2021-2030)
• Table 16: Drug-Eluting Stents Market in United Kingdom (2021-2030)
• Table 17: Drug-Eluting Stents Market in Italy (2021-2030)
• Table 18: Drug-Eluting Stents Market in Spain (2021-2030)
• Table 19: Drug-Eluting Stents Market in the Rest of Europe (2021-2030)
• Table 20: Drug-Eluting Stents Market in Asia-Pacific (2021-2030)
• Table 21: Drug-Eluting Stents Market in China (2021-2030)
• Table 22: Drug-Eluting Stents Market in Japan (2021-2030)
• Table 23: Drug-Eluting Stents Market in India (2021-2030)
• Table 24: Drug-Eluting Stents Market in Australia (2021-2030)
• Table 25: Drug-Eluting Stents Market in South Korea (2021-2030)
• Table 26: Drug-Eluting Stents Market in Rest of Asia-Pacific (2021-2030)
• Table 27: Drug-Eluting Stents Market in the Rest of the World (2021-2030)
• Table 28: Drug-Eluting Stents Market in the Middle East (2021-2030)
• Table 29: Drug-Eluting Stents Market in Africa (2021-2030)
• Table 30: Drug-Eluting Stents Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Drug-Eluting Stents Market in Global (2021-2030)
• Figure 3: Drug-Eluting Stents Market in Global by Type (2021-2030)
• Figure 4: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
• Figure 5: Drug-Eluting Stents Market in Global by Coating (2021-2030)
• Figure 6: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
• Figure 7: Drug-Eluting Stents Market in Global by End-User (2021-2030)
• Figure 8: Drug-Eluting Stents Market in Global by Geography (2021-2030)
• Figure 9: Drug-Eluting Stents Market in North America (2021-2030)
• Figure 10: Drug-Eluting Stents Market in the United States (2021-2030)
• Figure 11: Drug-Eluting Stents Market in Canada (2021-2030)
• Figure 12: Drug-Eluting Stents Market in Mexico (2021-2030)
• Figure 13: Drug-Eluting Stents Market in Europe (2021-2030)
• Figure 14: Drug-Eluting Stents Market in France (2021-2030)
• Figure 15: Drug-Eluting Stents Market in Germany (2021-2030)
• Figure 16: Drug-Eluting Stents Market in United Kingdom (2021-2030)
• Figure 17: Drug-Eluting Stents Market in Italy (2021-2030)
• Figure 18: Drug-Eluting Stents Market in Spain (2021-2030)
• Figure 19: Drug-Eluting Stents Market in the Rest of Europe (2021-2030)
• Figure 20: Drug-Eluting Stents Market in Asia-Pacific (2021-2030)
• Figure 21: Drug-Eluting Stents Market in China (2021-2030)
• Figure 22: Drug-Eluting Stents Market in Japan (2021-2030)
• Figure 23: Drug-Eluting Stents Market in India (2021-2030)
• Figure 24: Drug-Eluting Stents Market in Australia (2021-2030)
• Figure 25: Drug-Eluting Stents Market in South Korea (2021-2030)
• Figure 26: Drug-Eluting Stents Market in Rest of Asia-Pacific (2021-2030)
• Figure 27: Drug-Eluting Stents Market in the Rest of the World (2021-2030)
• Figure 28: Drug-Eluting Stents Market in the Middle East (2021-2030)
• Figure 29: Drug-Eluting Stents Market in Africa (2021-2030)
• Figure 30: Drug-Eluting Stents Market in South America (2021-2030)
• Figure 31: Market Drivers
• Figure 32: Market Barriers
• Figure 33: Marker Opportunities
• Figure 34: PORTER'S Five Force Analysis

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of cardiovascular disorders and the rising product developmental activities worldwide

The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030. The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021, it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with coronary artery disease (CAD) around the world.

As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease (PAD) globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Thus, the rising instances of cardiovascular conditions are driving a significant increase in demand for drug-eluting stents. As these conditions become more widespread globally, the need for effective, minimally invasive treatments like stenting is growing. Advances in stent technology, along with the increasing burden of heart and circulatory diseases, are making stents a vital component in treating these conditions, enhancing their role in both preventive and therapeutic healthcare strategies.

Increased product developmental activities by regulatory bodies worldwide is also slated to drive the market growth for drug-eluting stents. For example, in May 2022, Medtronic announced that it received the U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier(TM) drug-eluting stent (DES).

Hence, the interplay of all the above-mentioned factors is expected to drive the market for drug-eluting stents during the given forecast period from 2024 to 2030.

However, the risks and complications associated with drug-eluting stents, the stringent regulatory approval process, among others may prove to be challenging factors for the growth of the drug-eluting stents market.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-based coating category is expected to have a significant revenue share in 2023. This is due to the various features and applications of polymer-based coating of drug-eluting stents.

Polymer-based coatings on drug-eluting stents enhance the controlled release of therapeutic agents, making them highly effective in preventing restenosis in coronary arteries. These coatings are engineered to enable the gradual and targeted release of drugs, such as antiproliferative or anti-inflammatory agents, directly at the stent site. This helps in reducing smooth muscle cell proliferation and neointimal hyperplasia, which are common causes of restenosis. Additionally, polymers can be tailored for specific hydrophilicity and hydrophobicity, adjusting drug release rates to optimize therapeutic effects.

Applications of polymer-based coatings extend beyond coronary stents, as they are also used in peripheral artery disease, maintaining arterial patency in various vessels. Furthermore, these coatings can be combined with multiple drugs to address a broader range of complications, like restenosis and inflammation, providing versatile treatment options for different patient needs.

Therefore, the widespread uses of polymer-based coating, solidify the impact on the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall drug-eluting stents market:

Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for drug-eluting stents.

Product developmental activities initiated by regulatory bodies will further boost the market for drug-eluting stents. For example, in March 2024, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the AGENT(TM) Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional drug-eluting stents market growth. The presence of key players such as Abbott, Medtronic, and Boston Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the factors mentioned above provides a conducive growth environment for the North America region in the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market key players:

Some of the key market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co., Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

Recent Developmental Activities in the Drug-Eluting Stents Market:

• In September 2021, Biotronik received regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES).
• In June 2021, Abbott received product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S.
• In May 2021, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent, aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key takeaways from the Drug-Eluting Stents Market Report study

• Market size analysis for current drug-eluting stents market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the drug-eluting stents market
• Various opportunities available for other competitors in the drug-eluting stents market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current drug-eluting stents market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for drug-eluting stents market growth in the coming future?

Target audience who can be benefited from this drug-eluting stents market report study

• Drug-eluting stents providers
• Research organizations and consulting companies
• Drug-eluting stents related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in drug-eluting stents
• Various end-users who want to know more about the drug-eluting stents market and the latest developments in the drug-eluting stents market

Frequently Asked Questions for the Drug-Eluting Stents Market:

1. What are drug-eluting stents?

• The drug-eluting stent is a small mesh structure that is inserted into the artery to keep it open and also releases a medication that helps in preventing the formation of blood clots inside the stent.

2. What is the market for drug-eluting stents?

• The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030.

3. What are the drivers for the drug-eluting stents?

• The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the drug-eluting stents?

• Some of the major market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co.,Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

5. Which region has the highest share in the drug-eluting stents?

• Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Drug-Eluting Stents Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Drug-Eluting Stents Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Drug-Eluting Stents Market Key Factors Analysis

• 5.1. Drug-Eluting Stents Market Drivers
  • 5.1.1. Increasing incidence of chronic disorders
  • 5.1.2. Rising product developmental activities
  • 5.1.3. Growing instances of life-style related disorders
  • 5.1.4. Increasing preference for minimally invasive procedures
• 5.2. Drug-Eluting Stents Market Restraints and Challenges
  • 5.2.1. Risk and complications associated with drug-eluting stents
  • 5.2.2. Stringent regulatory approval process
• 5.3. Drug-Eluting Stents Market Opportunities
  • 5.3.1. Development of bioresorbable vascular scaffolds
  • 5.3.2. Integrating AI and robotics for stent placement

6. Drug-Eluting Stents Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Drug-Eluting Stents Market Assessment

• 7.1. By Type
  • 7.1.1. Coronary Stenting
  • 7.1.2. Peripheral Stenting
• 7.2. By Scaffold
  • 7.2.1. Platinum-Chromium
  • 7.2.2. Cobalt-Chromium
  • 7.2.3. Nitinol
  • 7.2.4. Others
• 7.3. By Coating
  • 7.3.1. Polymer-based Coating
    • 7.3.1.1. Biodegradable
    • 7.3.1.2. Non-Biodegradable
  • 7.3.2. Polymer-Free Coating
• 7.4. By Drug Type
  • 7.4.1. Everolimus
  • 7.4.2. Paclitaxel
  • 7.4.3. Others
• 7.5. By End-User
  • 7.5.1. Hospitals
  • 7.5.2. Ambulatory Surgical Centers
  • 7.5.3. Specialty Clinics
• 7.6. By Geography
  • 7.6.1. North America
    • 7.6.1.1. United States Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.1.2. Canada Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.1.3. Mexico Drug-Eluting Stents Market Size in USD million (2021-2030)
  • 7.6.2. Europe
    • 7.6.2.1. France Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2.2. Germany Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2.3. United Kingdom Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2.4. Italy Drug-Eluting Stents market size in USD million (2021-2030)
    • 7.6.2.5. Spain Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2.6. Rest of Europe Drug-Eluting Stents Market Size in USD million (2021-2030)
  • 7.6.3. Asia-Pacific
    • 7.6.3.1. China Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3.2. Japan Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3.3. India Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3.4. Australia Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3.5. South Korea Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3.6. Rest of Asia-Pacific Drug-Eluting Stents Market Size in USD million (2021-2030)
  • 7.6.4. Rest of the World (RoW)
    • 7.6.4.1. Middle East Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.4.2. Africa Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.4.3. South America Drug-Eluting Stents Market Size in USD million (2021-2030)

8. Drug-Eluting Stents Market Company and Product Profiles

• 8.1. Medtronic
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Abbott
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Boston Scientific Corporation
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. B. Braun Melsungen AG
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. BIOTRONIK SE & Co. KG
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Cook
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Terumo Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Lepu Medical Technology Co.,Ltd
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Microport Scientific Corporation
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Balton Sp.z.o.o
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. ENDOCOR GmbH
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Eurocor Tech GmbH
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Alvimedica
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Biosensors International Group, Ltd.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Meril Life Sciences Pvt. Ltd.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Translumina
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Sino Medical Sciences Technology Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. iVascular S.L.U
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Sahajanand Laser Technology Limited
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Cardionovum GmbH
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us